Nikhil C. Munshi, MD

Adjunct Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

Publications

  • Published 4/2/2026

    Alsina M, Shah N, Jagannath S, Kaufman JL, Siegel D, Munshi NC, Rosenblatt J, Lin Y, Jakubowiak AJ, Derman BA, Li A, Mao P, Fincker M, Yeri A, Martin N, Campbell TB, Finney O, Truppel-Hartmann A, Petrocca F, Berdeja JG, Raje N. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542. PMID: 41562447.

    Read at: PubMed

  • Published 3/26/2026

    Maura F, Samur M, Munshi N. Evolution of multiple myeloma from a genomic perspective. Blood. 2026 Mar 26; 147(13):1423-1432. PMID: 41359792.

    Read at: PubMed

  • Published 2/18/2026

    Moravej H, Rakhshandehroo T, Khan RMM, Rivet VM, Marcandalli E, Mantri SR, Taklifi P, Lee UJ, Louis BBV, Munaretto LA, Regan K, Farkash Z, Berland L, Gabr Z, Wolff AN, Kowalewski A, Allen HH, Nili A, Baral J, Mercadante D, Fulciniti M, Jacobson CA, Sperling AS, Nadeem O, Nia HT, Hemann M, Munshi NC, Rashidian M. Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Ra. J Immunother Cancer. 2026 Feb 18; 14(2). PMID: 41708145.

    Read at: PubMed

  • Published 2/3/2026

    Du T, Fang T, Pillai SC, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC. Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma. Blood. 2026 Feb 03. PMID: 41632828.

    Read at: PubMed

  • Published 1/16/2026

    Li C, Yang X, Shan J, Dickerson KA, Springer NA, Munshi NC, Batey RT, Disney MD. Mechanistically Defined Epoxide- and Aziridine-2-carboxamide Electrophiles Enable Stereoselective Covalent RNA Modulation. bioRxiv. 2026 Jan 16. PMID: 41648509.

    Read at: PubMed

View All 642 Publications:   View Full Profile in BUMC

Websites

Education

  • Maharaja Sayajirao University, MBBS
  • Maharaja Sayajirao University, MD

View all profiles